Japan Drug Makers Look To Cancer Biomedicines For New Products
This article was originally published in PharmAsia News
Executive SummaryAt least three of Japan's major drug makers are intensifying efforts to do well in the growing market for anti-cancer biopharmaceuticals that feature fewer side-effects than conventional drugs. Shionogi is the latest to join the field, with expectations of beginning by the end of the fiscal year clinical trials for vaccines to prevent bladder cancer. The drugs rely on proteins found only in cancerous cells use to induce an immune-system response. Eisai and Takeda Pharmaceutical also are developing biopharmaceuticals, with Eisai having just begun trials of a drug for colon and lung cancers, and Takeda set to begin selling colon- and rectal-cancer drugs early next year for an MNC, as well as completing trials on drugs of its own. (Click here for more - a subscription may be required
You may also be interested in...
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.